Skip to main content
ATRC
NASDAQ Industrial Applications And Services

AtriCure Q3 Revenue Up 15% to $154.5M; Full-Year Guidance Set at $606-610M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$60.35
Mkt Cap
$3.072B
52W Low
$25.36
52W High
$63
52W Position info
138% above low
Off High info
4.2% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

ATRC has more than doubled off its 52-week low of $25.36.

Summary

AtriCure reported Q3 2026 revenue of $154.5 million (+15.0% year over year), net income of $4.1 million and adjusted EBITDA of $26.8 million, and guided full-year 2026 revenue to about $606-610 million.


Key Events · Earnings and Guidance · ATRC

  • Q3 Revenue Grows 15% to $154.5M

    Worldwide revenue of $154.5 million rose 15.0% year over year (15.1% constant currency), with U.S. revenue of $128.0 million up 17.1% on cryoSPHERE MAX, EnCompass and AtriClip FLEX-Mini/PRO-Mini.

  • Profitability Expands Sharply

    Gross margin rose 180 basis points to 77.3%, net income was $4.1 million ($0.08 per diluted share) versus a $0.3 million loss a year ago, and adjusted EBITDA climbed 51% to $26.8 million.

  • Full-Year 2026 Guidance Issued

    Management projects 2026 revenue of approximately $606-610 million, adjusted EBITDA of $91-94 million, GAAP net income per share of $0.21-0.27 and adjusted EPS of $0.40-0.46, with continued positive cash generation.

  • Minimally Invasive Ablation Declines

    Minimally invasive ablation revenue fell to $5.4 million from $7.4 million in the U.S. as physicians adopt PFA catheters and Hybrid procedure volumes shrink — the one segment working against the growth story.


Analysis · ATRC · Industrial Applications And Services

The growth and margin story held together in the third quarter. Revenue of $154.5 million rose 15.0% year over year, gross margin expanded 180 basis points to 77.3%, and adjusted EBITDA jumped 51% to $26.8 million. A $4.1 million net profit replaced a small loss a year ago, and management now guides full-year 2026 revenue to roughly $606-610 million, with adjusted EBITDA of $91-94 million and adjusted EPS of $0.40-0.46. The soft spot is minimally invasive ablation, where sales fell as physicians shift to PFA catheters — a competitive substitution worth tracking against the strength in pain management and appendage management. With the stock near its 52-week high, the print and guidance are the near-term test of whether that valuation holds.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ATRC was trading at $60.35 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $25.36 to $63.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ATRC - Latest Insights

ATRC
Nov 04, 2026, 2:02 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $64.90
Real-time Price: $54.91 info
Change: -$9.99 (-15%) info
Market Cap: $2.801B info
ATRC
Nov 03, 2026, 4:01 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $60.41
Real-time Price: $54.91 info
Change: -$5.50 (-9%) info
Market Cap: $2.801B info
ATRC
Jul 27, 2026, 1:07 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $37.31
Real-time Price: $54.91 info
Change: +$17.60 (+47%) info
Market Cap: $2.801B info
ATRC
Jul 23, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $34.71
Real-time Price: $54.91 info
Change: +$20.19 (+58%) info
Market Cap: $2.801B info
ATRC
May 19, 2026, 4:21 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $28.80
Real-time Price: $54.91 info
Change: +$26.11 (+91%) info
Market Cap: $2.801B info